[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658642":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":13,"interventions":13,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":18,"collaborators":13,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":13,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":13,"enrollmentInfo":29,"targetDuration":13,"studyType":32,"phases":13,"briefSummary":33,"conditions":34,"keywords":13,"overallStatus":37,"whyStopped":13,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":13},{"fullName":5,"class":6},"Fundación Santa Fe de Bogota","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Change in low-density lipoprotein cholesterol (LDL-C) levels","Change in low-density lipoprotein cholesterol (LDL-C) levels following treatment with evolocumab or alirocumab in patients with hyperlipidemia and\u002For atherosclerotic cardiovascular disease (ASCVD) during the study period.","January-2018 to July-2024",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","RETROSPECTIVE","Patients over 18 years of age with hyperlipidemia and\u002For atherosclerotic heart disease in Bogotá.",{"type":19,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100658642","pcsk9-inhibitors-in-hyperlipidemia-and-atherosclerosis-100658642",false,"NCT07856264","PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis","Real-World Experience With the Use of PCSK9 Inhibitors in Patients With Hyperlipidemia and Atherosclerotic Cardiovascular Disease at a University Hospital in Bogotá, Colombia","Inclusion Criteria:\n\n* Patients aged 18 years or older with a clinical diagnosis of hyperlipidemia and\u002For atherosclerotic cardiovascular disease (ASCVD) according to ESC\u002FEAS guidelines who also meet the following criteria:\n\nPatients who initiated treatment with evolocumab or alirocumab between 2018 and 2024.\n\nPatients who received at least one dose of evolocumab or alirocumab. Patients followed by the Cardiology Department at Fundación Santa Fe de Bogotá. Patients with at least one measured and\u002For calculated low-density lipoprotein cholesterol (LDL-C) level within the 6 months prior to initiation of evolocumab or alirocumab.\n\nExclusion Criteria:\n\n* Patients with prior exposure to PCSK9 inhibitor therapy within the 6 months before initiation of evolocumab or alirocumab.\n\nPatients without at least one LDL-C measurement after initiation of PCSK9 inhibitor therapy.\n\nPatients without at least one LDL-C measurement within the 6 months prior to initiation of evolocumab or alirocumab.\n\nPatients with incomplete medical records from which identification or contact information cannot be obtained.","ALL","18 Years",{"count":30,"type":31},100,"ESTIMATED","OBSERVATIONAL","PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease. This retrospective observational study aims to describe changes in low-density lipoprotein cholesterol (LDL-C) levels following the use of PCSK9 inhibitors in adult patients with hyperlipidemia and\u002For atherosclerotic cardiovascular disease treated at Fundación Santa Fe de Bogotá between 2018 and 2024. The study will also describe patients' clinical characteristics, treatment effectiveness, safety, adherence, and barriers to treatment access. Data will be obtained from medical records, cardiology records, and telephone interviews when needed to complete missing information.",[35,36],"Hyperlipidemia","Atherosclerotic Cardiovascular Disease (ASCVD)","NOT_YET_RECRUITING","2026-09-28",{"date":40,"type":41},"2026-10-02","ACTUAL",{"date":43,"type":31},"2027-02-01",{"date":45,"type":31},"2027-07-31",{"name":5,"class":6}]